Literature DB >> 12925268

A systematic review of atypical antipsychotic drugs in schizophrenia.

A-M Bagnall1, L Jones, L Ginnelly, R Lewis, J Glanville, S Gilbody, L Davies, D Torgerson, J Kleijnen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12925268     DOI： 10.3310/hta7130

Source DB:  PubMed          Journal:  Health Technol Assess        ISSN： 1366-5278            Impact factor:   4.014


× No keyword cloud information.
  34 in total

Review 1.  [Shock trauma room management of spinal injuries in the framework of multiple trauma. A systematic review of the literature].

Authors:  A Woltmann; V Bühren
Journal:  Unfallchirurg       Date:  2004-10       Impact factor: 1.000

Review 2.  Modern antipsychotic drugs: a critical overview.

Authors:  David M Gardner; Ross J Baldessarini; Paul Waraich
Journal:  CMAJ       Date:  2005-06-21       Impact factor: 8.262

3.  Clinical trial design: horses for courses.

Authors:  John R Geddes
Journal:  World Psychiatry       Date:  2009-02       Impact factor: 49.548

4.  Prevalence and trends in the use of antipsychotic medications during pregnancy in the U.S., 2001-2007: a population-based study of 585,615 deliveries.

Authors:  Sengwee Toh; Qian Li; T Craig Cheetham; William O Cooper; Robert L Davis; Sascha Dublin; Tarek A Hammad; De-Kun Li; Pamala A Pawloski; Simone P Pinheiro; Marsha A Raebel; Pamela E Scott; David H Smith; William V Bobo; Jean M Lawrence; Inna Dashevsky; Katherine Haffenreffer; Lyndsay A Avalos; Susan E Andrade
Journal:  Arch Womens Ment Health       Date:  2013-02-07       Impact factor: 3.633

Review 5.  The estimation of utility weights in cost-utility analysis for mental disorders: a systematic review.

Authors:  Michael Sonntag; Hans-Helmut König; Alexander Konnopka
Journal:  Pharmacoeconomics       Date:  2013-12       Impact factor: 4.981

6.  Geissoschizine methyl ether, an alkaloid from the Uncaria hook, improves remyelination after cuprizone-induced demyelination in medial prefrontal cortex of adult mice.

Authors:  Shoko Morita; Kouko Tatsumi; Manabu Makinodan; Hiroaki Okuda; Toshifumi Kishimoto; Akio Wanaka
Journal:  Neurochem Res       Date:  2013-11-06       Impact factor: 3.996

7.  Modelling approaches: the case of schizophrenia.

Authors:  Bart M S Heeg; Joep Damen; Erik Buskens; Sue Caleo; Frank de Charro; Ben A van Hout
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

8.  Cost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United States.

Authors:  Nicolas M Furiak; Haya Ascher-Svanum; Robert W Klein; Lee J Smolen; Anthony H Lawson; Robert R Conley; Steven D Culler
Journal:  Cost Eff Resour Alloc       Date:  2009-04-07

9.  Long-acting risperidone injection: efficacy, safety, and cost-effectiveness of the first long-acting atypical antipsychotic.

Authors:  Pierre Chue
Journal:  Neuropsychiatr Dis Treat       Date:  2007-02       Impact factor: 2.570

10.  Adherence and persistence to typical and atypical antipsychotics in the naturalistic treatment of patients with schizophrenia.

Authors:  Haya Ascher-Svanum; Baojin Zhu; Douglas E Faries; Jonathan P Lacro; Christian R Dolder; Xiaomei Peng
Journal:  Patient Prefer Adherence       Date:  2008-02-02       Impact factor: 2.711
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.